Changes in BTG1 Gene Expression ‎Level in People with Gastric Cancer ‎and Its Comparison with Healthy ‎People

Alibahar, Hamid; Paridar, Yousef; Mard-soltani, Maysam; Haji Hosseini, Reza

doi:10.30473/eab.2021.58999.1829

Document Type : Article

Authors

¹ Ph. D., Department of Biochemistry, Payame Noor ‎University (PNU), P.O. Box 19395-4697, Tehran, Iran

² Assistant Professor, Gastroenterology Clinic, Dezful ‎University of Medical Sciences, Dezful, Iran

³ Assistant Professor, Department of Clinical ‎Biochemistry, Faculty of Medical Sciences, Dezful ‎University of Medical Sciences, Dezful, Iran

⁴ Professor, Department of Biochemistry, Payame Noor ‎University (PNU), P.O. Box 19395-4697, Tehran, Iran

https://doi.org/10.30473/eab.2021.58999.1829

Abstract

Gastric cancer (GC) is one of the most common types of cancer and the second leading cause of cancer mortality. Delay in diagnosis and lack of screening are the main causes of high mortality from this disease. Finding an accurate and effective diagnostic biomarker seems to be essential for effective treatment of GC. In this regard, using a gastroscope, we collected tissue samples from patients with GC and healthy individuals. The obtained samples were used to extract their RNA using Trizol solution kit. RNA samples were used for qRT-PCR using specific primers designed for BTG1 and GAPDH genes. QRT-PCR results were analyzed using 2^-ΔCt method and various statistical tests using SPSS software. In total, 40 samples of GC and healthy controls were collected and their demographic information was recorded. RNA extraction produced the amount of RNA required for qRT-PCR. The qRT-PCR results showed that BTG1 expression was significantly decreased in GC samples. According to the obtained results, it can be concluded that the reduction of BTG1 expression can act as an accurate biomarker for GC. This gene can also be an indicator of GC pathogenicity. These results could indicate possible diagnostic and therapeutic applications of BTG1 for GC.

Keywords

20.1001.1.23222387.1401.10.4.3.3

References

Bray, F.; et al. (2018). Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: a cancer journal for clinicians; 68(6): 394-424.

Baek, S.M.; Kim, N.; Kwon, Y.J.; et al. (2020). Role of Serum Pepsinogen II and Helicobacter pylori Status in the Detection of Diffuse-Type Early Gastric Cancer in Young Individuals in South Korea. Gut Liver; 14(4): 439-449. doi:10.5009/gnl19091.p-18

Chen, X. Q.; Meng, F. Q.; Xiong, H.; Wang, Y. L.; Tang, W. H.; Zou, Y. M. (2020). Identification of BTG1 status in solid cancer for future researches using a system review and meta-analysis. Current Medical Science; 40(1): 85-94. doi:10.1007/s11596-020-2150-z,

Fonseca-Camarillo, G.; Furuzawa-Carballeda, J.; Priego-Ranero, Á.A.; Martínez-Benítez, B.; Barreto-Zúñiga, R.; Yamamoto-Furusho, J.K. (2021). Expression of TOB/BTG family members in patients with inflammatory bowel disease. Scand J Immunol; 93: e13004. p-3

Jie, M.; et al. (2020). CircMRPS35 suppresses gastric cancer progression via recruiting KAT7 to govern histone modification. Molecular cancer; 19(1): p. 1-16.p-3

Kim, M.; Jo, H.; Kwon, Y.; Kim, Y.; Jung, H.S.; Jeoung, D. (2020). Homoharringtonine inhibits allergic inflammations by regulating NF-κB-miR-183-5p-BTG1 Axis. Front Pharmacol; 11: 1032. 10.3389/fphar.p4-18

Kuo, M.L.; et al. (2003). Arf induces p53-dependent and -independent antiproliferative genes. Cancer Res.; 63(5): 1046-53.p-4-16

Kanda, M.; et al. (2015). B‑cell translocation gene 1 serves as a novel prognostic indicator of hepatocellular carcinoma. International journal of oncology; 46(2): 641-648.P-17

Kanda, M.; et al. (2015). Diversity of clinical implication of B-cell translocation gene 1 expression by histopathologic and anatomic subtypes of gastric cancer. Digestive diseases and sciences; 60(5): 1256-1264.P-17-18

Kim, N.; Jung, H.C. (2010). The role of serum pepsinogen in the detection of gastric cancer. Gut and liver; 4(3): 307. p-4-18

Lu, Y.; et al. (2014). BTG1 expression in thyroid carcinoma: diagnostic indicator and prognostic marker. International journal of oncology; 45(4): 1574-1582. P-16

Livak, K.J.; Schmittgen, T.D. (2001). Analysis of relative gene expression data using real-time quantitative PCR and the 2^−ΔΔCT method. methods, 25(4): 402-408.p-4

Malekzadeh, R., M.H. Derakhshan, and Z. Malekzadeh, (2009). Gastric cancer in Iran: epidemiology and risk factors. p-4-16

Qian, Y.; et al. (2019). The treatment effects and the underlying mechanism of B cell translocation gene 1 on the oncogenesis of brain glioma. Journal of cellular biochemistry; 120(8): 13310-13320. P-17P-4

Rawla, P.; Barsouk, A. (2019). Epidemiology of gastric cancer: global trends, risk factors and prevention. Przeglad gastroenterologiczny, 14(1): 26.

Sung, H.; Ferlay, J.; Siegel, R.L. (2020). Global cancer statistics: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. 2021.p-3

Song, M.; et al. (2018). Serum pepsinogen 1 and anti‐Helicobacter pylori IgG antibodies as predictors of gastric cancer risk in Finnish males. Alimentary pharmacology & therapeutics; 47(4): 494-503.p-3

Strand, M.S.; Lockhart, A.C.; (2017). Fields, Genetics of gastric cancer. Surgical Clinics, 97(2): 345-370.p-3

Sullivan, C.B.; et al. (2019). Survival outcomes for advanced cutaneous squamous cell carcinoma of the head and neck. Annals of Otology, Rhinology & Laryngology; 128(10): 949-955. p-3

Sasajima, H.; Nakagawa, K.; Yokosawa, H. (2002). Antiproliferative proteins of the BTG/Tob family are degraded by the ubiquitin‐proteasome system. European journal of biochemistry; 269(14): 3596-3604. p-4

Schmittgen, T.D.; Livak, K.J. (2008). Analyzing real-time PCR data by the comparative C T method. Nature protocols; 3(6): 1101.p-6

Steeghs, E.M.; et al. (2019). Copy number alterations in B-cell development genes, drug resistance, and clinical outcome in pediatric B-cell precursor acute lymphoblastic leukemia. Scientific reports; 9(1): 1-11. P-16

Sun, G.; et al. (2015). B cell translocation gene 1 reduces the biological outcome of kidney cancer through induction of cell proliferation, cell cycle arrest, cell apoptosis and cell metastasis. International journal of molecular medicine; 35(3): 777-783.P-16

Sun, G.; et al. (2014). Expression of BTG1 in hepatocellular carcinoma and its correlation with cell cycles, cell apoptosis, and cell metastasis. Tumor Biology; 35(12): 11771-11779.P-18-6

Sun, G.; et al. (2014). The expression of BTG1 is downregulated in nasopharyngeal carcinoma and possibly associated with tumour metastasis. Molecular biology reports; 41(9): 5979-5988.P-16

Sheng, S.; Zhao, C.; Sun, G. (2014). BTG1 expression correlates with the pathogenesis and progression of breast carcinomas. Tumor Biology; 35(4): 3317-3326.P-18

Sun, G.; et al. (2014). The expression of BTG1 is downregulated in NSCLC and possibly associated with tumor metastasis. Tumor Biology; 35(4): 2949-2957.P-18-16

Winkler, G.S. (2010). The mammalian anti‐proliferative BTG/Tob protein family. Journal of cellular physiology; 222(1): 66-72.p-4-17

Wang, Y.; et al. (2019). PUM2 promotes glioblastoma cell proliferation and migration via repressing BTG1 expression. Cell structure and function; 44(1): 29-39. P-17

Zhang, S.-Q.; et al. (2017). miR-511 promotes the proliferation of human hepatoma cells by targeting the 3′ UTR of B cell translocation gene 1 (BTG1) mRNA. Acta Pharmacologica Sinica; 38(8): p. 1161-1170.p-4

Zhu, R., et al., (2015). Upregulation of BTG1 enhances the radiation sensitivity of human breast cancer in vitro and in vivo. Oncology reports; 34(6): p. 3017-3024.p-16-18

Zheng, H.-c., et al., (2015). BTG1 expression correlates with pathogenesis, aggressive behaviors and prognosis of gastric cancer: a potential target for gene therapy. Oncotarget; 6(23): 19685.p-16

Zhao, Y., et al., (2013). BTG1 expression correlates with the pathogenesis and progression of ovarian carcinomas. International journal of molecular sciences; 14(10): 19670-19680.p-16

Zhu, R., et al., (2013). BTG1 inhibits breast cancer cell growth through induction of cell cycle arrest and apoptosis. Oncology reports; 30(5): p. 2137-2144.p-17

Zhu, J.; Han, S. (2019). Lidocaine inhibits cervical cancer cell proliferation and induces cell apoptosis by modulating the lncRNA-MEG3/miR-421/BTG1 pathway. American journal of translational research; 11(9): 5404.P-17

Zhang, J.; Dong, W. (2020). Expression of B cell translocation gene 1 protein in colon carcinoma and its clinical significance. Recent patents on anti-cancer drug discovery; 15(1):78-85. p-16

Yuniati, L., et al., (2019). Tumor suppressors BTG1 and BTG2: Beyond growth control. Journal of cellular physiology; 234(5): 5379-5389.P-16

Yufang Huang, Jiawei Zheng, Ting Tan, Li Song, Shanshan Huang, Yan Zhang, Lin Lin, Jingnan Liu, Peichan Zheng, Xiong Chen, Xi Chen, Xuenong Ouyang, (2017). BTG1 low expression in pancreatic ductal adenocarcinoma is associated with a poorer prognosis, The International Journal of Biological Markers, doi:10.5301/ijbm.5000310, 33, (189-194), p. 1663-1670.p-4

Experimental animal Biology

Changes in BTG1 Gene Expression ‎Level in People with Gastric Cancer ‎and Its Comparison with Healthy ‎People

References

References

Volume 10, Issue 4 - Serial Number 40
July 2022
Pages 35-46

Changes in BTG1 Gene Expression ‎Level in People with Gastric Cancer ‎and Its Comparison with Healthy ‎People

References

References

Volume 10, Issue 4 - Serial Number 40July 2022Pages 35-46

Volume 10, Issue 4 - Serial Number 40
July 2022
Pages 35-46